Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 4/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1931528 | 0.86 | ELANE (0.38) | USP2SMN1; SMN2ELANE | |
| SCHEMBL7299181 | 0.82 | ELANE (0.36) | ELANE | |
| SCHEMBL1931297 | 0.82 | ELANE (0.36) | ELANE | |
| SCHEMBL16038481 | 0.81 | USP2 (0.41) | USP2SMN1; SMN2ELANERECQLGAA | |
| SCHEMBL7308248 | 0.81 | ELANE (0.35) | ELANE | |
| SCHEMBL16050853 | 0.79 | ELANE (0.38) | ELANE | |
| SCHEMBL3264014 | 0.79 | TSHR (0.39) | RECQLKDM4EMEN1LMNAMAPT | |
| SCHEMBL10000017 | 0.78 | ALDH1A1 (0.31) | ELANE | |
| SCHEMBL7308268 | 0.78 | ELANE (0.37) | ELANE | |
| Formic Acid SCHEMBL28145465 | 0.78 | ELANE (0.34) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040706-B2 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040706-B2 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-0780386-B1 | Matrix metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-5932595-A | ANTIARTHRITIC AGENT; MULTIPLE SCLEROSIS; OSTEOPOROSIS; RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTIULCER AGENT | SYNTEX (U.S.A.) INC. (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0780386-A1 | Matrix metalloprotease inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | USP2 420/4885SMN1; SMN2 2913/4885ELANE 2507/4885 |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | USP2 420/4885SMN1; SMN2 2913/4885ELANE 2507/4885 |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | USP2 420/4885SMN1; SMN2 2913/4885ELANE 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.